Royal Philips reported Q2 2026 comparable sales growth of 4% to EUR 4.4 billion, driven by growth across all segments. Income from operations reached EUR 609 million, including a EUR 186 million US tariff refund benefit. Adjusted EBITA margin improved to 16.4%, and free cash flow was EUR 222 million. The company reiterated its full-year 2026 comparable sales growth outlook of 3%-4.5% and updated its Adjusted EBITA margin outlook to 13.5%-14.0% and free cash flow to EUR 1.5-1.7 billion to reflect the tariff refund. Philips also completed the distribution of its 2025 dividend of EUR 0.85 per common share. The company operates in the health technology industry, providing medical imaging, patient monitoring, and personal health solutions.